Vertex bolsters C-suite with a pair of promotions by Amirah Al Idrus Tuesday, October 1, 2019 Carmen Bozic, M.D., Vertex's new head of global medicines development and medical affairs, will take over the CMO post April 1.
Kleiner, GV drive gene editing startup Trucode to $34M round by Nick Paul Taylor Tuesday, September 10, 2019 Trucode will use the money to advance gene editing assets designed to correct the mutations behind diseases including cystic fibrosis.
Proteostasis nabs Belous from Galapagos for cystic fibrosis push by Nick Paul Taylor Tuesday, July 23, 2019 The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.
BillionToOne launches prenatal screener for inherited disorders by Conor Hale Monday, July 1, 2019 Following its $15 million series A round earlier this year, BillionToOne has launched its first product for commercial and clinical use.
Orkambi debate in U.K. revives the myth of a people-funded drug by Ben Adams Tuesday, June 11, 2019 The question over who is really responsible for the costly creation of drugs has arisen in the U.K.
3. Symdeko by Arlene Weintraub Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.
AbbVie buys Galapagos’ cystic fibrosis assets despite weak data by Nick Paul Taylor Thursday, October 25, 2018 The deal follows two underwhelming clinical trial readouts that suggested the drugs may struggle to compete with Vertex.
New tactics against antibiotic-resistant infections by Arlene Weintraub Thursday, September 27, 2018 Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.
Boehringer lands option on cystic fibrosis gene therapy by Nick Paul Taylor Monday, August 6, 2018 Boehringer will work with British academics and Oxford BioMedica to develop an inhaled, lentiviral vector-based gene therapy for cystic fibrosis.
Celtaxsys’ cystic fibrosis drug reduces exacerbations in phase 2 by Conor Hale Thursday, August 2, 2018 Celtaxsys’ cystic fibrosis drug cleared phase 2 by reducing lung exacerbations, such as heavy coughing episodes that can lead to irreversible damage.
